KURA insider trading
NasdaqGS HealthcareKura Oncology, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
Company website: kuraoncology.com
KURA insider activity at a glance
FilingIQ has scored 218 insider transactions for KURA since Nov 10, 2015. The most recent filing in our index is dated Mar 23, 2026.
Across the full history, 13 open-market purchases
and 94 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on KURA insider trades is 56.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest KURA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding KURA
Frequently asked
- How many insider trades does FilingIQ track for KURA?
- FilingIQ tracks 218 Form 4 insider transactions for KURA (Kura Oncology, Inc.), covering filings from Nov 10, 2015 onwards. 4 of those were filed in the last 90 days.
- Are KURA insiders net buyers or net sellers?
- Across the full Form 4 history for KURA, 13 transactions (6%) were open-market purchases and 94 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does KURA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is KURA in?
- Kura Oncology, Inc. (KURA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $718.76M.
Methodology & sources
Every KURA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.